Childhood absence epilepsy (CAE) is one of the most common forms of pediatric epilepsy, accounting for between 10 and 17 % of all cases of childhood onset epilepsies. 1 CAE is defined by age-related onset, clinical and electrographic characteristics, and a presumed genetic etiology. • a double-blind randomized controlled design;
placebo-controlled trials that compared either gabapentin (GBP), 17 LTG 13 or levetiracetam (LEV) 12 with placebo (see Table 2 ).
Sato and colleagues compared VPA and ESM in a randomised double-blind response-conditional crossover study. 16 Sixteen naïve and 29 drug-resistant patients aged three to 18 years with absence seizures were included.
They received either VPA with placebo for six weeks followed by ESM with placebo for six weeks or the same regimen in the reverse order.
However, patients who were responders during the first treatment period were not crossed over to the alternative treatment. At the end of the first period of the crossover, there was a trend toward a non-significant higher seizure-free rate with VPA (40.9 %) than with ESM (34.8 %). However, when both treatment periods were included in the analysis, the probability of response to VPA was 37.3 ± 3.5 versus 38.3 ± 3.4 % to ESM.
Childhood Absence Epilepsy-A Review of Treatment Strategies and Perspectives for the Future LEV was evaluated in a two-week placebo-controlled trial in children and adolescents with newly diagnosed absence seizures. 12 The patients were and lamotrigine (LTG) may be considered as candidates for initial monotherapy in CAE", without hierarchy between these three drugs. 18 Importantly, beyond the issue of anti-epileptic efficacy, these studies also poorly addressed the effectiveness of AEDs, which combine both long-term efficacy and tolerability. Indeed, safety issues and specifically cognitive outcomes, were not adequately addressed.
In this context, the National Institutes of Health-funded study published in the New England Journal of Medicine in 2010 by Glauser and colleagues is momentous 14 (see Table 3 ). Indeed, this large multicenter double-blind RCT, which compared ESM, VPA and LTG in children with newly diagnosed CAE, addressed most of the limitations of previous studies:
• it enroled a large population, homogeneous in age distribution, seizure type and EEG criteria;
• the dose regimen was flexible, adapted to clinical and EEG responses; and • a clinically relevant primary endpoint was used, defined by the proportion of patients who remained on treatment and were free from both clinical and EEG seizures at the final assessment.
Four-hundred and fifty-three children were randomized with a median age of seven years five months: 156 were assigned to ESM, 149 to LTG and 148 to VPA. Dosage was increased every one to two weeks over a 
What Could be Recommended in Daily Practice and What Information is Missing?
As detailed above, some evidence is available to guide first-line therapy in newly diagnosed CAE:
• ESM and VPA are the most effective AEDs in this clinical setting;
• cognitive performances might be better with ESM than with VPA, justifying the use of the former as first-line therapy;
• although LTG has anti-absence properties, it proved to be less efficacious than both ESM and VPA in CAE; and
• no other AED has demonstrated efficacy in CAE, including GBP, which was found to be inefficacious.
Moreover, AEDs known to potentially aggravate other idiopathic generalized epilepsy syndrome, such as carbamazepine, oxcarbazepine or phenytoine, 20 should be avoided. However, several questions remain unanswered and future studies are required to refine therapeutic decisions.
One of the main issues is the long-term outcome. Indeed, the longest follow-up in studies with robust methodology was 20 weeks, 14 whereas
RCTs with longer follow-up have used open-label designs or small sample sizes. [9] [10] [11] 15 This limitation underlies several questions. About 15 % of children with CAE will progress to juvenile myoclonic epilepsy and/or suffer generalized tonic-clonic seizures at adolescence. 5 ESM has been shown to be inefficacious to suppress generalised tonic-clonic seizures. 21 In this context, the comparative incidence of generalized tonic-clonic seizures between ESM and VPA cohorts will be of particular interest.
Similarly, although several RCTs, including the Glauser study, 14 enroled patients with juvenile absence epilepsy, the preference of ESM over VPA in this specific syndrome should be questioned by the frequent co-existence of generalized tonic-clonic seizures. Another issue is related to chronic
Childhood Absence Epilepsy-A Review of Treatment Strategies and Perspectives for the Future Similarly, for the small percentage of females who will need to continue treatment during adolescence and adulthood to ensure seizure freedom, optimisation of therapy should also take into consideration the available information about the comparative effects of individual drugs on fetal and post-natal development.
In most studies, the responder rates varied between 40 and 60 %, highlighting the fact that a significant proportion of patients will require second-line monotherapy and eventually polytherapy. Evidence-based data about the management of refractory CAE are lacking. 23 According to the similar efficacy of ESM and VPA in newly diagnosed CAE, switching from one to the other in case of treatment failure seems to be the most reasonable choice. When patients fail to respond to both ESM and VPA, the probability of achieving seizure freedom with LTG monotherapy is likely to be low. In this context, the combination of AEDs might be proposed, with particular interest in the association of VPA/LTG, which showed some evidence of a positive pharmacodynamic interaction. 24 Despite the paucity of data, LEV 25 and zonisamide 26 have also been proposed in the treatment of refractory absence seizures.
A ketogenic diet 27 and vagal nerve stimulation 28 might be discussed as alternative non-pharmacologic therapies.
Whatever the therapeutic choice, one of the main remaining grey areas in the management of CAE is the issue of treatment duration. About 12 to 19 % of children with CAE suffer from seizure recurrence after the withdrawal of AEDs. 29, 30 As for other epileptic syndromes, 31 a delay of two years seizure freedom is usually retained before starting to taper AEDs.
This general recommendation might be modulated by the specific characteristics of the epileptic syndrome, such as the presumptive link between the dynamic of CAE and that of brain development, as well as by the presence of individual risk factors, including absence status before or during AED treatment, development of tonic-clonic or myoclonic seizures after onset of treatment and abnormal background on initial EEG. 5 However, we still lack precise and robust data to guide us on the optimal treatment duration in patients with CAE.
Conclusion
Despite the major impact of the recent study reported by Glauser and colleagues, 14 there is still a gap between the prevalence of CAE in pediatric epilepsies and the paucity of available data on its therapeutic management. Beyond the recommendation of preferring ESM as a first-line therapy in newly diagnosed CAE, most of the other issues still require further investigation. n 
